With lower statin doses, again vs. placebo, the higher risk for T2DM was +11% with 10 mg/day rosuvastatin and it decreased to + 4% with 10 mg atorvastat- in, whereas 10–20 mg pravastatin resulted even protective (−10%). Compared to higher doses, lower statin doses were associated with only moderate advantage in the induction of new-onset T2DM risk (80 vs. 10 mg atorvastatin: +1%; 40 vs. 10–20 mg pravastatin: +7%; 20 vs. 10 mg rosuvastatin: +12%). According to this meta-analysis, different types and doses of statins show different potential to increase the incidence of T2DM, depicting a new scenario of statin treatment that emphasizes a personalized therapeutic strategy [24] (Fig. 1).